At Sucampo, we value the people who make our organization great. The brightest minds come to Sucampo to build our scientific legacy; we don’t just expect that you’ll be great, we expect you to get better while you’re here. Our employees’ empowerment drives us toward our mission and their passion ensures our lasting success. Because our employees are key to our success, we provide an environment where great people can leverage great ideas to make great things happen.
We strive to be one of the best biopharmaceutical companies to work for and we invest in a workplace that inspires greatness – our people are expected to take advantage of development opportunities and benefit from competitive pay and benefits.
As a Sucampo employee, you can expect both a challenging and a rewarding career that will allow you the opportunity to work alongside the industry’s top talent.
Here at Sucampo, we collaborate to progress strategies and we innovate to drive science.
Together, we relentlessly pursue the right drug in the right place for the right patient; we do it the right way, by being empowered, entrepreneurial and accountable.
We remain aligned to solve unmet medical needs though scientific exploration and innovation to improve the lives of patients, caregivers and their families.
We know balancing a professional career with personal commitments is key to an employee’s success. Sucampo offers a generous and comprehensive package of paid time off and benefits coverage.
Benefits are aligned with local legislation and practices in each country and are established to provide a healthy work-life balance for our employees.
Sucampo operates under a pay-for-performance philosophy. This compensation philosophy is designed to:
Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.